mechanism of action of glp 1 agonist GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes Glucagon-like peptide 1 (GLP-1) -

Some researchers have highlighted post-treatment study findings that have shown that people tend to suffer from a high risk of weight regain after stopping these drugs

10.1007/s12325-009-0014-9 182 TanX.HuJ

Retatrutide is not approved for clinical use as of 2026

Added to that, it is constantly growing in scale with an estimated projection of overweight and obese adults at 1.35 billion and 573 million, respectively, by the year 2030 [4]

It has shown significant promise as an effective intervention against type 2 diabetes (T2D) and excessive body weight, resulting in the United States Food and Drug Administration (FDA) approving its use against both conditions in May 2022 for T2D and November 2023 for obesity

Results The systematic search initially identified a total of 2494 studies initially